Name: Ixazomib | MLN2238
Brand: Ambeed
SKU: A172813

NCT02765854	Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less <<	Phase 2	Recruiting	September 2020	United States, Georgia ... More >> Grady Memorial Hospital Recruiting Atlanta, Georgia, United States, 30303 Contact: Stephanie McMillan, RN, MSN 404-778-1361 sjmcmil@emory.edu Emory University/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Jennifer Shipp 404-778-4191 jennifer.shipp@emory.edu United States, Michigan University of Michigan/Rogel Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Craig Cole, MD colec@med.umich.edu United States, Missouri Washington University/Siteman Cancer Center Recruiting Saint Louis, Missouri, United States, 63110 Contact: Ravi Vij, MD rvij@wustl.edu Less <<
NCT02400437	Waldenstrom's Macroglobulinemi... More >>a Less <<	Phase 2	Active, not recruiting	September 2021	United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT02158975	Lymphoma, T-Cell	Phase 2	Completed	-	United States, Michigan ... More >> University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 Less <<
NCT02158975	-		Completed	-	-
NCT03376672	Multiple Myeloma	Phase 2	Recruiting	December 31, 2027	Finland ... More >> Helsinki University Central Hospital Recruiting Helsinki, Finland Contact: Pekka Anttila, MD pekka.anttila@hus.fi Central Finland Central Hospital Recruiting Jyväskylä, Finland Contact: Anu Sikiö, MD anu.sikio@ksshp.fi Kainuu Central Hospital Recruiting Kajaani, Finland Contact: Kristiina Kananen, MD, PhD kristiina.kananen@kainuu.fi Kymenlaakso Central Hospital Recruiting Kotka, Finland Contact: Anu Räsänen, MD anu.rasanen@carea.fi Kuopio University Hospital Recruiting Kuopio, Finland Contact: Anu Partanen, MD anu.partanen@kuh.fi Päijät-Häme Cebtral Hospital Not yet recruiting Lahti, Finland Contact: Maija Mikkola, MD maija.mikkola@phsotey.fi Oulu University Hospital Recruiting Oulu, Finland Contact: Marjaana Säily, MD, PhD marjaana.saily@ppshp.fi Tampere University Hospital Recruiting Tampere, Finland Contact: Marja Sankelo, MD, PhD marja.sankelo@pshp.fi Turku University Hospital Recruiting Turku, Finland Contact: Mervi Putkonen, MD, PhD mervi.putkonen@tyks.fi Lithuania VIlnius University Hospital Not yet recruiting Vilnius, Lithuania Contact: Valdas Peceliunas, MD, PhD Norway Forde Central Hospital South Not yet recruiting Forde, Norway Contact: Damian Lukasz Szatkowski, MD Oslo University Hospital Not yet recruiting Oslo, Norway Contact: Fredrik Schjesvold, MD Stavanger University Hospital Not yet recruiting Stavanger, Norway Contact: Einar Haukås, MD Trondheim University Hospital Not yet recruiting Trondheim, Norway Contact: Anders Waage, MD, Prof. Sweden Borås University Hospital Not yet recruiting Borås, Sweden Contact: Ulf-Henrik Mellqvist, MD Göteborg University Hospital Not yet recruiting Göteborg, Sweden Contact: Cecilie Blimark, MD Halmstad Hospital Region Halland Not yet recruiting Halmstad, Sweden Contact: Conny Karlsson, MD Linköping University Hospital Not yet recruiting Linköping, Sweden Contact: Lucia Ahlberg, MD Sunderby Hospital Region Norrbotten Not yet recruiting Luleå, Sweden Contact: Birgitta Lauri, MD Lund University Hospital Not yet recruiting Lund, Sweden Contact: Markus Hansson, MD Helsingborg Hospital Skane Not yet recruiting Skane, Sweden Contact: Per Axelsson, MD Karolinska University Hospital Not yet recruiting Stockholm, Sweden Contact: Hareth Nahi, Ass.Prof.PhD hareth.nahi@karolinska.se Uddevalla Hospital Not yet recruiting Uddevalla, Sweden Contact: Johanna Abelsson, MD Uppsala University Hospital Not yet recruiting Uppsala, Sweden Contact: Kristina Carlson, MD Varberg Hospital Not yet recruiting Varberg, Sweden Contact: Mikael Olsson, MD Örebro University Hospital Not yet recruiting Örebro, Sweden Contact: Olle Linder, MD Less <<
NCT02461888	Multiple Myeloma	Phase 2	Recruiting	May 2019	United Kingdom ... More >> Queen Elizabeth Medical Centre Recruiting Birmingham, United Kingdom, B15 2TH Heart of England NHS Foundation Trust Recruiting Birmingham, United Kingdom, B9 5ST Royal Bournemouth General Hospital Recruiting Bournemouth, United Kingdom, BH7 7DW University Hospital Bristol NHS Foundation Trust Recruiting Bristol, United Kingdom, BS1 3NU North Tees and Hartlepool NHS Foundation Trust Recruiting Hartlepool, United Kingdom, TS24 9AH Leeds Teaching Hospitals NHS Trust Recruiting Leeds, United Kingdom, LS9 7TF Royal Liverpool and Broadgreen University Hospital NHS Trust Recruiting Liverpool, United Kingdom, L7 8XP Barts and the London NHS Trust Recruiting London, United Kingdom, E1 1BB University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom, NW1 2PG Guy's and St Thomas's NHS Foundation Trust Recruiting London, United Kingdom, SE1 9RT Royal Marsden Hospital Recruiting London, United Kingdom, SW3 6JJ Imperial College Healthcare NHS Trust Recruiting London, United Kingdom, W2 1NY The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Nottingham University Hospital NHS Trust Recruiting Nottingham, United Kingdom, NG7 2UH Churchill Hospital Recruiting Oxford, United Kingdom, OX3 7LE Sheffield Teaching Hospitals NHS Foundation Trust Recruiting Sheffield, United Kingdom, S5 7AU Southampton University Hospital NHS Trust Recruiting Southampton, United Kingdom, SO16 6YD The Royal Wolverhampton Hospital NHS Trust Recruiting Wolverhampton, United Kingdom, WV10 0QP Less <<
NCT02250300	Patients Undergoing Allogeneic... More >> Hematopoietic Stem Cell Transplantation Less <<	Phase 1 Phase 2	Active, not recruiting	September 2022	United States, Wisconsin ... More >> Froedtert Hospital and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT02042989	Advanced Cancers	Phase 1	Active, not recruiting	June 2022	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03416374	Relapsed and/or Refractory Mul... More >>tiple Myeloma Less <<	Phase 4	Recruiting	May 31, 2021	Japan ... More >> Kameda Medical Center Recruiting Kamogawa, Chiba, Japan The Jikei University Kashiwa Hospital Recruiting Kashiwa, Chiba, Japan Ogaki Municipal Hospital Recruiting Ogaki, Gifu, Japan Gunma University Hospital Recruiting Maebashi, Gunma, Japan Shibukawa Medical Center Recruiting Shibukawa, Gunma, Japan Kobe city Medical Center General Hospital Recruiting Kobe, Hyogo, Japan Kanazawa University Hospital Recruiting Kanazawa, Ishikawa, Japan Iwate Medical University Recruiting Morioka, Iwate, Japan Yokohama Municipal Citizen's Hospital Recruiting Yokohama, Kanagawa, Japan Suwa Red Cross Hospital Recruiting Suwa, Nagano, Japan Dokkyo Medical University Recruiting Koshigaya, Saitama, Japan Juntendo University Hospital Recruiting Bunkyo-ku, Tokyo, Japan Nippon Medical School Hospital Recruiting Bunkyo-ku, Tokyo, Japan Nihon University Itabashi Hospital Recruiting Itabashi-ku, Tokyo, Japan The Cancer Institute Hospital of JFCR Recruiting Koto-ku, Tokyo, Japan The Jikei University Hospital Recruiting Minato-ku, Tokyo, Japan Kyorin University Hospital Recruiting Mitaka, Tokyo, Japan Japanese Red Cross Medical Center Recruiting Shibuya-ku, Tokyo, Japan Tokyo Disaster Medical Center Recruiting Tachikawa, Tokyo, Japan Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Recruiting Hiroshima, Japan Kyoto Kuramaguchi Medical Center Recruiting Kyoto, Japan Niigata Cancer Center Hospital Recruiting Niigata, Japan Osaka Red Cross Hospital Recruiting Osaka, Japan Less <<
NCT03012880	Plasma Cell Myeloma	Phase 2	Recruiting	April 15, 2019	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji K. Kumar Less <<
NCT03202628	Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less <<	Phase 2	Recruiting	July 24, 2022	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Prashant Kapoor Less <<
NCT01659658	Relapsed or Refractory Systemi... More >>c Light Chain Amyloidosis Less <<	Phase 3	Recruiting	August 31, 2022	-
NCT01645930	Multiple Myeloma	Phase 1	Completed	-	Hong Kong ... More >> Pokfulam, Hong Kong Shatin, Hong Kong Korea, Republic of Incheon, Korea, Republic of Seoul, Korea, Republic of Singapore Singapore, Singapore Less <<
NCT01645930	-		Completed	-	-
NCT02389517	Plasma Cell Myeloma ... More >> Residual Disease Less <<	Phase 2	Recruiting	March 2, 2022	United States, Illinois ... More >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Andrzej J. Jakubowiak 773-834-1592 ajakubowiak@medicine.bsd.uchicago.edu Principal Investigator: Andrzej J. Jakubowiak Less <<
NCT03492138	Multiple Myeloma	Phase 1 Phase 2	Recruiting	March 15, 2023	United States, New York ... More >> Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Lisa La, MS 212-241-7873 Lisa.La@mssm.edu Less <<
NCT02384746	Breast Cancer	Phase 1	Recruiting	August 2020	United States, New Hampshire ... More >> Dartmouth-Hitchcock Medical Center Recruiting Lebanon, New Hampshire, United States, 03756 Contact: Research Nurse, RN 800-639-6918 Cancer.Research.Nurse@Dartmouth.edu Principal Investigator: Gary N Schwartz, MD Less <<
NCT03763162	Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less <<	Phase 2	Not yet recruiting	December 31, 2023	United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Hans C. Lee 713-792-2860 Principal Investigator: Hans C. Lee Less <<
NCT02547662	Plasma Cell Leukemia ... More >> Plasma Cell Myeloma Plasmacytoma Less <<	Phase 2	Recruiting	December 15, 2020	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji K. Kumar United States, Tennessee Sarah Cannon Cancer Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Jessica L. Piggee 615-329-6838 Jessica.piggee@sarahcannon.com Principal Investigator: Jesus G. Berdeja Less <<
NCT03236792	AL Amyloidosis	Phase 1 Phase 2	Recruiting	June 2020	United States, New York ... More >> Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Keren Osman, MD Contact: Sonia Rai, MHA,MD 212-241-6021 sonia.rai@mssm.edu Principal Investigator: Keren Osman, MD Columbia University Medical Center Not yet recruiting New York, New York, United States, 10032 Contact: Suzanne Lentzsch, MD,PhD Memorial Sloan Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Contact: Heather Landau, MD Contact: Beth Hoover HooverE@mskcc.org Principal Investigator: Heather Landau, MD Less <<
NCT01335685	-		Completed	-	-
NCT02119468	Refractory Plasma Cell Myeloma... More >> Recurrent Plasma Cell Myeloma Less <<	Phase 1 Phase 2	Active, not recruiting	November 2018	United States, Arizona ... More >> Mayo Clinic Scottsdale, Arizona, United States, 85259 United States, California City of Hope Medical Center Duarte, California, United States, 91010 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Tennessee Sarah Cannon Research Institute (SCRI) Nashville, Tennessee, United States, 37203 Less <<
NCT02410694	Multiple Myeloma	Phase 2	Recruiting	June 2019	Austria ... More >> Ordensklinikum, KH der Barmherzigen Schwestern Linz, Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie Recruiting Linz, Oberösterreich, Austria, 4010 Contact: Andreas Petzer, MD 00437327677 ext 7345 andreas.petzer@ordensklinikum.at Principal Investigator: Andreas Petzer, MD KH der Elisabethinen Linz, 1. Interne Abteilung Recruiting Linz, Oberösterreich, Austria, 4020 Contact: Daniel Lechner, MD 00437327676 ext 64412 daniel.lechner@elisabethinen.or.at Principal Investigator: Daniel Lechner, MD Klinikum Wels-Grieskirchen, IV. Interne Abteilung Recruiting Wels, Oberösterreich, Austria, 4600 Contact: Thomas Kühr, MD 00437242415 ext 3452 thomas.kuehr@klinikum-wegr.at Principal Investigator: Thomas Kühr, MD Medizinische Universitätsklinik Graz, Klinische Abteilung für Hämatologie Recruiting Graz, Steiermark, Austria, 8036 Contact: Peter Neumeister, MD 0043316385 ext 14086 peter.neumeister@medunigraz.at Principal Investigator: Peter Neumeister, MD UK Innsbruck, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie und Onkologie Recruiting Innsbruck, Tirol, Austria, 6020 Contact: Eberhard Gunsilius, MD 0043512504 ext 80669 eberhard.gunsilius@tirol-kliniken.at Principal Investigator: Eberhard Gunsilius, MD A.ö. BK Kufstein, Abteilung für Innere Medizin Recruiting Kufstein, Tirol, Austria, 6330 Contact: August Zabernigg, MD 004353726966 ext 3001 august.zabernigg@bkh-kufstein.at Principal Investigator: August Zabernigg, MD LKH Feldkirch, Interne E Recruiting Feldkirch, Vorarlberg, Austria, 6830 Contact: Alois Lang, MD 00435522303 ext 2301 alois.lang@lkhf.at Principal Investigator: Alois Lang, MD Kepler Universitätsklinikum Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie Recruiting Linz, Austria, 4021 Contact: Michael Fridrik, MD 00435768083 ext 1610 michael.fridrik@akh.linz.at Principal Investigator: Michael Fridrik, MD Universitätsklinik der PMU Universitätsklinik für Innere Medizin III Recruiting Salzburg, Austria, 5020 Contact: Richard Greil, MD 004357255 ext 25801 r.greil@salk.at Principal Investigator: Richard Greil, MD Wilhelminenspital Recruiting Vienna, Austria, A-1160 Contact: Niklas Zojer, MD 0043149150 ext 2151 niklas.zojer@wienkav.at Contact: Heidrun Forstner heidrun.forstner@extern.wienkav.at Principal Investigator: Niklas Zojer, MD KH der Barmherzigen Brüder Wien, Innere Medizin Recruiting Wien, Austria, 1020 Contact: Elisabeth Küenburg, MD 0043121121 ext 5159 elisabeth.kueenburg@bbwien.at Principal Investigator: Elisabeth Küenburg, MD Med. Universität Wien, Universitätsklinik f. Innere Medizin I, Klin. Abt. f. Hämatologie u. Hämostaseologie Recruiting Wien, Austria, 1090 Contact: Heinz Gisslinger, MD 0043140400 ext 54640 heinz.gisslinger@meduniwien.ac.at Principal Investigator: Heinz Gisslinger, MD Czechia Faculty Hospital Brno and Faculty of Medicine MU Brno 2nd Internal Clinic Recruiting Brno, Czechia, 639 00 Contact: Ludek Pour, MD lpour@fnbrno.cz Principal Investigator: Ludek Pour, MD Fakultní nemocnice Ostrava Recruiting Ostrava-Poruba, Czechia, 708 52 Contact: Roman Hajek, MD roman.hajek@fno.cz Principal Investigator: Roman Hajek, MD Germany Universitätsklinikum Leipzig - AöR Selbstständige Abteilung für Hämatologie, Internistische Onkologie und Hämostaseologie Recruiting Leipzig, Germany, 04103 Contact: Dietger Niederwieser, MD Dietger.Niederwieser@medizin.uni-leipzig.de Principal Investigator: Dietger Niederwieser, MD Universitätsklinikum Tübingen, Innere Medizin II Recruiting Tubingen, Germany, 72076 Contact: Katja Weisel, MD katja.weisel@med.uni-tuebingen.de Principal Investigator: Katja Weisel, MD Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II Zentrum Innere Medizin Recruiting Wurzburg, Germany, 97080 Contact: Stefan Knop, MD knop_s@klinik.uni-wuerzburg.de Principal Investigator: Stefan Knop, MD Less <<
NCT01335685	Multiple Myeloma	Phase 1 Phase 2	Completed	-	United States, New Hampshire ... More >> Lebanon, New Hampshire, United States United States, West Virginia Morgantown, West Virginia, United States Canada, British Columbia Vancouver, British Columbia, Canada Canada, Ontario Toronto, Ontario, Canada Canada Quebec, Canada Czechia Brno, Czechia Praha 2, Czechia Spain Badalona, Spain Barcelona, Spain Madrid, Spain Salamanca, Spain San Sebastian, Spain Sevilla, Spain United Kingdom Bournemouth, United Kingdom Brighton, United Kingdom Cambridge, United Kingdom London, United Kingdom Nottingham, United Kingdom Oxford, United Kingdom Uxbridge, United Kingdom Less <<
NCT00830869	Advanced Non-hematologic Malig... More >>nancies Less <<	Phase 1	Completed	-	United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Washington University of Washington- Seattle Cancer Care Seattle, Washington, United States, 98109 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT01912222	-		Completed	-	-
NCT02440464	Multiple Myeloma	Phase 2	Active, not recruiting	March 2023	United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States, 35294 United States, California City of Hope National Medical Center Duarte, California, United States, 91010 United States, Florida H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33624 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 BMT Northside Atlanta, Georgia, United States, 30342 United States, Illinois Loyola University Medical Center Maywood, Illinois, United States, 60153 United States, Kentucky University of Kentucky Lexington, Kentucky, United States, 40536 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27705 United States, Ohio Ohio State/Arthur G. James Cancer Hospital Columbus, Ohio, United States, 43210 United States, Texas University of Texas /MD Anderson CRC Houston, Texas, United States, 77030 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 United States, Wisconsin University of Wisconsin Hospital & Clinics Madison, Wisconsin, United States, 53792 Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53211 Less <<
NCT01864018	Amyloidosis P... More >>lasma Cell Myeloma Less <<	Phase 1 Phase 2	Recruiting	October 22, 2020	United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Peter L. Bergsagel United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji K. Kumar Less <<
NCT02921893	Plasmacytoma ... More >>POEMS Syndrome Less <<	Phase 2	Recruiting	October 15, 2021	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Angela Dispenzieri Less <<
NCT03457142	Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less <<	Phase 2	Recruiting	November 8, 2020	United States, New York ... More >> Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263 Contact: Kelvin P. Lee 716-845-4106 Kelvin.Lee@roswellpark.org Principal Investigator: Kelvin P. Lee Less <<
NCT03683277	Multiple Myeloma ... More >> Relapsed and Refractory Multiple Myeloma Genetic Condition Less <<	Phase 2	Not yet recruiting	October 1, 2023	-
NCT01912222	Advanced Solid Tumors ... More >> Hematologic Malignancies Less <<	Phase 1	Completed	-	United States, Kansas ... More >> Fairway, Kansas, United States United States, Ohio Cleveland, Ohio, United States United States, Texas Dallas, Texas, United States Houston, Texas, United States Less <<
NCT02481310	Adult Burkitt Lymphoma ... More >> B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma Diffuse Large B-Cell Lymphoma MYC Gene Mutation Plasmablastic Lymphoma Less <<	Phase 1 Phase 2	Recruiting	July 2020	United States, Illinois ... More >> Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Barbara Pro, MD 312-695-6180 Principal Investigator: Barbara Pro, MD United States, Massachusetts Tufts University Recruiting Medford, Massachusetts, United States, 02155 Contact: Andreas Klein, MD 617-636-2694 Principal Investigator: Andreas Klein, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08901 Contact: Andrew Evens, DO, MSc Principal Investigator: Andrew Evens, DO, MSc United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Deepa Jagadeesh, MD 216-445-6503 Principal Investigator: Deepa Jagadeesh, MD United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Mehdi Hamadani, MD 414-805-0505 Principal Investigator: Mehdi Hamadani, MD Less <<
NCT02253316	Multiple Myeloma	Phase 2	Recruiting	January 31, 2023	United States, California ... More >> City of Hope Recruiting Duarte, California, United States, 91010 Contact: Nitya Nathwani, MD 626-256-4673 ext 65295 nnathwani@coh.org Principal Investigator: Nitya Nathwani, MD Sub-Investigator: Ahmed Aribi, MD Sub-Investigator: Ibrahim Aldoss, MD Sub-Investigator: Monzr Al-Malki, MD Sub-Investigator: Elizabeth Budde, MD Sub-Investigator: Ji-Lian Cai, MD Sub-Investigator: Thai Cao, MD Sub-Investigator: Robert Chen, MD Sub-Investigator: Leonardo Farol, MD Sub-Investigator: Stephen Forman, MD Sub-Investigator: Alex Herrera, MD Sub-Investigator: Myo Htut, MD Sub-Investigator: Chatchada Karanes, MD Sub-Investigator: Khaled Samer, MD Sub-Investigator: Amrita Krishnan, MD Sub-Investigator: Matthew Mei, MD Sub-Investigator: Auayporn Nademanee, MD Sub-Investigator: Ryotaro Nakamura, MD Sub-Investigator: Margaret O'Donnell, MD Sub-Investigator: Pablo Parker, MD Sub-Investigator: Leslie Popplewell, MD Sub-Investigator: Michael Rosenzweig, MD Sub-Investigator: Firoozeh Sahebi, MD Sub-Investigator: Amandeep Salhotra, MD Sub-Investigator: Tanya Siddiqi, MD Sub-Investigator: David Snyeder, MD Sub-Investigator: George Somlo, MD Sub-Investigator: Ricardo Spielberger, MD Sub-Investigator: Anthony Stein, MD Sub-Investigator: Jasmine Zain, MD University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Thomas G. Martin, MD 415-353-2051 tom.martin@ucsf.edu Principal Investigator: Thomas G. Martin, MD United States, Colorado Colorado Blood Cancer Institute Recruiting Denver, Colorado, United States, 80218 Contact: Tara K Gregory, M.D. 720-754-4800 Tara.Gregory@HealthONECares.com Principal Investigator: Tara K Gregory, M.D. Sub-Investigator: Alireza B Maris, M.D. Sub-Investigator: Jeffrey V Matous, M.D. Sub-Investigator: Peter A McSweeney, M.D. Sub-Investigator: Richard Nash, M.D. Sub-Investigator: Marcello Rotta, M.D. Sub-Investigator: Michael T Tees, M.D. United States, Georgia Emory University - Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Jonathan L Kaufman, MD 404-778-1900 jlkaufm@emory.edu United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jeffrey A Zonder, MD 313-576-8732 zonderj@karmanos.org Principal Investigator: Jeffrey A. Zonder, M.D. Sub-Investigator: Abhinav Deol, MD Sub-Investigator: Radhakrishnan Ramchandren, MD Sub-Investigator: Melissa Runge-Morris, MD Sub-Investigator: Charles Schiffer, MD Sub-Investigator: Jay Yang, MD Sub-Investigator: Steven Burt, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Francis K Buadi, M.D. (507) 538-3270 Buadi.Francis@mayo.edu Principal Investigator: Francis K Buadi, M.D. Sub-Investigator: Angela Dispenzieri, M.D. Sub-Investigator: Matthew T Drake, M.D., Ph.D. Sub-Investigator: Amie L Fonder, PA-C Sub-Investigator: Morie Gertz, M.D. Sub-Investigator: Ronald S Go, M.D. Sub-Investigator: Wilson I Gonsalves, M.D. Sub-Investigator: Suzanne R Hayman, M.D. Sub-Investigator: Miriam A Hobbs, APRN, CNP, DNP Sub-Investigator: Yi (Lisa) L Hwa, APRN, CNP, DNP Sub-Investigator: Prashant Kapoor, M.D. Sub-Investigator: Taxiarchis Kourelis, M.D. Sub-Investigator: Shaji K Kumar, M.D. Sub-Investigator: Nelson Leung, M.D. Sub-Investigator: Yi Lin, M.D., Ph.D. Sub-Investigator: John A Lust, M.D., Ph.D. Sub-Investigator: S. Vincent Rajkumar, M.D. Sub-Investigator: Stephen J Russell, M.D., Ph.D. Sub-Investigator: Thomas E Witzig, M.D. Sub-Investigator: Steven R Zeldenrust, M.D, Ph.D. United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 62864 Contact: Ravi Vij, M.D. 314-454-8323 rvij@wustl.edu Principal Investigator: Ravi Vij, M.D. Sub-Investigator: Camille Abboud, M.D. Sub-Investigator: John DiPersio, M.D., Ph.D. Sub-Investigator: Todd Fehniger, M.D., Ph.D. Sub-Investigator: Armin Ghobadi, M.D. Sub-Investigator: Megan Jacoby, M.D., Ph.D. Sub-Investigator: Jesse Keller, M.D. Sub-Investigator: Iskra Pusic, M.D. Sub-Investigator: Rizwan Romee, M.D. Sub-Investigator: Mark Schreoder, M.D. Sub-Investigator: Keith Stockerl-Goldstein, M.D. Sub-Investigator: Michael Tomasson, M.D. Sub-Investigator: Geoffrey Uy, M.D. Sub-Investigator: Matthew Walter, M.D. Sub-Investigator: Lukas Wartman, M.D. Sub-Investigator: John Welch, M.D., Ph.D. Sub-Investigator: Peter Westervelt, M.D., Ph.D. United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Ajai Chari, M.D. 212-241-7873 ajai.chari@mountsinai.org Principal Investigator: Ajai Chari, M.D. Sub-Investigator: Sundar Jagannath, M.D. Sub-Investigator: Hearn Cho, M.D. Sub-Investigator: Samir Parekh, M.D. Sub-Investigator: Deepu Madduri, M.D. United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Ashley Rosko, M.D. 614-293-7807 Ashley.Rosko@osumc.edu Principal Investigator: Ashley Rosko, M.D. Sub-Investigator: Don Benson, Jr., M.D., Ph.D. Sub-Investigator: Jonathan Brammer, M.D. United States, Tennessee Tennessee Oncology, PLLC Recruiting Nashville, Tennessee, United States, 37203 Contact: Jesus Berdeja, M.D. 615-329-7274 jberdeja@tnonc.com Principal Investigator: Jesus Berdeja, M.D. Less <<
NCT02831686	Multiple Myeloma ... More >> Relapsed and/or Refractory Multiple Myeloma Less <<	Phase 1	Recruiting	July 2019	United States, New Jersey ... More >> Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Nikoletta Lendvai, MD, PhD 212-639-3368 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Nikoletta Lendvai, MD 212-639-3368 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Nikoletta Lendvai, MD, PhD 212-639-3368 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Nikoletta Lendvai, MD, PhD 212-639-3368 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Nikoletta Lendvai, MD, PhD 212-639-5126 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Nikoletta Lendvai, MD, PhD 212-639-3368 Contact: Ola Landgren, MD, PhD 212-639-5126 Principal Investigator: Nikoletta Lendvai, MD, PhD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States Contact: Nikoletta Lendvai, MD, PhD 212-639-3368 Less <<
NCT02070458	Recurrent Adult Acute Myeloid ... More >>Leukemia Refractory Acute Myeloid Leukemia Less <<	Phase 1	Completed	-	United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Less <<
NCT01318902	Light-Chain Amyloidosis	Phase 1	Completed	-	United States, Massachusetts ... More >> Tufts Medical Center Boston, Massachusetts, United States, 02111 Boston Medical Center Boston, Massachusetts, United States, 02118 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Mount Sinai Medical Center New York, New York, United States, 10029 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Canada, Ontario University Health Network Toronto, Ontario, Canada, M5G 2M9 France CHU Limoges, Department of Hematology and Cell Therapy, Reference Center for AL amyloidosis Limoges Cedex, France, 87042 Germany Universitatsklinikum Heidelberg Innere Medizin V; Hamatologie, Onkologie und Rheumatologie Heidelberg, Germany, D-69120 Italy Amyloidosis Research & Treatment Center, Fondazione IRCCS Policlinico San Matteo Pavia, Italy, 27100 Less <<
NCT02542657	Myeloma	Phase 1 Phase 2	Recruiting	July 2020	United States, California ... More >> University of California San Diego Recruiting La Jolla, California, United States, 92093-0960 Contact: Caitlin Costello 858-822-6387 ccostello@ucsd.edu Principal Investigator: Caitlin Costello University of California Irvine Recruiting Orange, California, United States, 92868 Contact: Elizabeth Brem, MD 714-456-5164 ebrem@uci.edu University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Joseph M. Tuscano 916-734-3771 jtuscano@ucdavis.edu Principal Investigator: Joseph M. Tuscano Less <<
NCT02633059	Loss of Chromosome 17p ... More >> Recurrent Plasma Cell Myeloma Less <<	Phase 1 Phase 2	Recruiting	May 13, 2021	United States, California ... More >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Michael A. Rosenzweig 626-471-9300 mrosenzweig@coh.org Principal Investigator: Michael A. Rosenzweig United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Vivek Roy United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Leonard T Heffner, M.D. 404-778-1900 winship.referrals@emoryhealthcare.org Principal Investigator: Leonard T. Heffner, M.D. United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Craig E. Cole 734-647-8901 colec@med.umich.edu Principal Investigator: Craig E. Cole Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jeffrey A. Zonder 313-576-8732 zonderj@karmanos.org Principal Investigator: Jeffrey A. Zonder United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji Kumar United States, New Jersey Hackensack University Medical Center Recruiting Hackensack, New Jersey, United States, 07601 Contact: Adolfo A. Aleman 551-996-8176 Adolfo.Aleman@Hackensackmeridian.org Principal Investigator: Joshua Richter United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Craig C. Hofmeister 614-293-7807 craig.hofmeiser@osumc.edu Principal Investigator: Craig C. Hofmeister Less <<
NCT00963820	Multiple Myeloma	Phase 1	Completed	-	United States, Arizona ... More >> Mayo Clinic- Scottsdale Scottsdale, Arizona, United States, 85259 United States, California James R. Berenson, MD, Inc West Hollywood, California, United States, 90069 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Weill-Cornell Medical College New York, New York, United States, 10011 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 Less <<
NCT03590652	Relapsed/Refractory Multiple M... More >>yeloma Less <<	Phase 2	Recruiting	October 1, 2021	United States, California ... More >> UCSD Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Caitlin Costello, MD 858-822-6600 ccostello@ucsd.edu Contact: Jesika Reiner jreiner@ucsd.edu Less <<
NCT00963820	-		Completed	-	-
NCT02057640	Multiple Myeloma ... More >> Kahler Disease Plasma-Cell Myeloma Myelomatosis Less <<	Phase 1 Phase 2	Active, not recruiting	December 2018	United States, Ohio ... More >> University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT01383928	Multiple Myeloma	Phase 1 Phase 2	Completed	-	United States, California ... More >> UCSF Medical Center Berkeley, California, United States, 94704 City of Hope National Medical Center Duarte, California, United States, 91010 Stanford University Stanford, California, United States, 94305 United States, Florida H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Maryland Associates of Oncology/Hematology PC Rockville, Maryland, United States, 20850 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 Michigan State University Lansing, Michigan, United States, 48910 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10021 Mount Sinai Hospital New York, New York, United States, 31406 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27705 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Mercy St Anne Hospital Toledo, Ohio, United States, 43623 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Tennessee SCRI Tennessee Oncology Nashville Nashville, Tennessee, United States, 37203 United States, Texas Baylor Sammons Cancer Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Cancer Care Specialist Fairfax, Virginia, United States, 22031 Virginia Cancer Specialists PC Fairfax, Virginia, United States, 22031 Less <<
NCT02504359	Plasma Cell Leukemia ... More >> Recurrent Plasma Cell Myeloma Less <<	Phase 1	Recruiting	July 1, 2021	United States, North Carolina ... More >> Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Cristina Gasparetto 919-668-1017 cristina.gasparetto@duke.edu Principal Investigator: Cristina Gasparetto United States, Oregon OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Emma C. Scott 503-494-2398 scottem@ohsu.edu Principal Investigator: Emma C. Scott Less <<
NCT03433001	-		Recruiting	March 31, 2021	Japan ... More >> Takeda Selected Site Recruiting Tokyo, Japan Less <<
NCT03399539	Recurrent Plasma Cell Myeloma ... More >> t(11;14) Less <<	Phase 1 Phase 2	Recruiting	March 2, 2022	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji K. Kumar Less <<
NCT01564537	Relapsed Multiple Myeloma ... More >> Refractory Multiple Myeloma Less <<	Phase 3	Active, not recruiting	December 1, 2020	-
NCT01830816	Multiple Myeloma\|Advanced Soli... More >>d Tumors Less <<	PHASE1	COMPLETED	2016-11-18	Winship Cancer Institute, Emor... More >>y University, Atlanta, Georgia, 30322, United States\|Illinois Cancer Care, Peoria, Illinois, 61615, United States\|University of Kansas Cancer Center, Clinical Research Center, Fairway, Kansas, 66205, United States\|University of Maryland, Baltimore, Maryland, 21201, United States\|Mount Sinai Medical Center, New York, New York, 31406, United States\|University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States\|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States\|Mary Crowley Cancer Research Centers Medical City, Dallas, Texas, 75201, United States\|Institute of Oncology Hematology Biomedical Research, Laredo, Texas, 78041, United States\|University of Texas Health Science Center San Antonio, San Antonio, Texas, 78229, United States\|University Health Network, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT01564537	-		Active, not recruiting	-	-
NCT01415882	Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less <<	Phase 2	Recruiting	April 1, 2019	United States, Arizona ... More >> Mayo Clinic in Arizona Active, not recruiting Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Vivek Roy United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Shaji K. Kumar Less <<
NCT01383928	-		Completed	-	-
NCT02619682	Plasma Cell Myeloma ... More >> Transplant-Related Carcinoma Less <<	Phase 2	Recruiting	-	United States, Washington ... More >> Fred Hutchinson Cancer Research Center Recruiting Seattle, Washington, United States, 98109 Contact: Leona A. Holmberg 206-667-6447 lholmber@fredhutch.org Principal Investigator: Leona A. Holmberg Less <<
NCT02897830	Multiple Myeloma	Phase 2	Active, not recruiting	April 2021	France ... More >> University Hosptial Toulouse Toulouse, France, 31000 Less <<
NCT01850524	Multiple Myeloma	Phase 3	Active, not recruiting	February 22, 2021	-
NCT03506360	Recurrent Plasma Cell Myeloma	Phase 2	Recruiting	March 29, 2024	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Yi Lin, M.D., Ph.D. Less <<
NCT00893464	Lymphoma	Phase 1	Completed	-	United States, California ... More >> Tower Cancer Research Center Beverly Hills, California, United States, 90211 United States, Colorado Rocky Mountain Cancer Center Denver, Colorado, United States, 80218 United States, Kansas Kansas University Medical Center Westwood, Kansas, United States, 66160 United States, New York Cornell University New York City, New York, United States, 10021 United States, Pennsylvania Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 United States, Wisconsin University of Wisconsin Madison Madison, Wisconsin, United States, 53792 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 Less <<
NCT03213158	Kidney Diseases ... More >> End Stage Renal Disease Less <<	Phase 2	Recruiting	December 2019	United States, Wisconsin ... More >> University of Wisconsin Hospital and Clinics Recruiting Madison, Wisconsin, United States, 53792 Less <<
NCT03506373	Recurrent Waldenstrom Macroglo... More >>bulinemia Refractory Waldenstrom Macroglobulinemia Less <<	Phase 2	Recruiting	May 1, 2025	United States, Florida ... More >> Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Asher A. Chanan-Khan, M.D., M.B.B.S. Less <<
NCT02916771	Smoldering Multiple Myeloma	Phase 2	Recruiting	April 2024	United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Irene M Ghobrial, MD 617-632-4198 Irene_Ghobrial@dfci.harvard.edu Principal Investigator: Irene M Ghobrial, MD Less <<
NCT02339922	Chronic Lymphocytic Leukemia ... More >> Follicular Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia Less <<	Phase 2	Recruiting	-	United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Ajay K. Gopal 206-606-2037 agopal@u.washington.edu Principal Investigator: Ajay K. Gopal Less <<
NCT01953783	Advanced Solid Tumors ... More >> Lymphoma Less <<	Phase 1	Unknown	March 2016	United States, Ohio ... More >> Cleveland, Ohio, United States Less <<
NCT01217957	Multiple Myeloma	Phase 1 Phase 2	Completed	-	United States, Arizona ... More >> Mayo Clinic Arizona Scottsdale, Arizona, United States, 85259 United States, California Cedars Sinai Medical Center Los Angeles, California, United States, 90048 United States, Colorado Rocky Mountain Cancer Center Rose Denver, Colorado, United States, 80218 United States, Connecticut Cancer Center of Central Connecticut Southington, Connecticut, United States, 06489 United States, Florida Mayo Clinic Jacksonville Jacksonville, Florida, United States, 32224 Mt Sinai Medical Center Miami Beach, Florida, United States, 33140 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Harry and Jeannette Weinberg Cancer Center at Franklin Square Hospital Baltimore, Maryland, United States, 21215 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 United States, New York New York Presbyterian Hospital - Weill-Cornell New York, New York, United States, 10021 United States, Tennessee Sarah Cannon Cancer Center Nashville, Tennessee, United States, 37203 United States, West Virginia W VA University Mary Babb Randolph Cancer Center Morgantown, West Virginia, United States, 26506 United States, Wisconsin The Medical College of Wisconsin, Inc. Milwaukee, Wisconsin, United States, 53226 Less <<
NCT01217957	-		Completed	-	-
NCT02917941	Relapsed and/or Refractory Mul... More >>tiple Myeloma Less <<	Phase 2	Active, not recruiting	August 4, 2019	Japan ... More >> Nagoya, Aichi, Japan Narita, Chiba, Japan Shibukawa, Gunma, Japan Fukuyama, Hiroshima, Japan Kobe, Hyogo, Japan Ibaraki, Ibaragi, Japan Sagamihara, Kanagawa, Japan Sendai, Miyagi, Japan Ikoma, Nara, Japan Sunto, Shizuoka, Japan Utsunomiya, Tochigi, Japan Bunkyo-ku, Tokyo, Japan Koto-ku, Tokyo, Japan Shibuya-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Tachikawa, Tokyo, Japan Chiba, Japan Fukuoka, Japan Niigata, Japan Okayama, Japan Osaka, Japan Less <<
NCT02004275	Multiple Myeloma in Relapse	Phase 1 Phase 2	Recruiting	-	-
NCT00893464	-		Completed	-	-
NCT02697383	Multiple Myeloma ... More >> High Risk Smoldering Multiple Myeloma Less <<	Phase 1	Active, not recruiting	February 2019	United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States Memoral Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 Memorial Sloan Kettering Bergen Montvale, New Jersey, United States, 07645 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Rockville Centre Rockville Centre, New York, United States Less <<
NCT02412228	Multiple Myeloma	Phase 2	Recruiting	September 2019	United States, Rhode Island ... More >> Memorial Hospital of Rhode Island Withdrawn Pawtucket, Rhode Island, United States, 02860 Rhode Island Hospital Recruiting Providence, Rhode Island, United States, 02903 Contact: Kayla Rosati 401-863-3000 kayla_rosati@brown.edu Principal Investigator: John Reagan, MD The Miriam Hospital Recruiting Providence, Rhode Island, United States, 02906 Contact: Kayla Rosati 401-863-3000 kayla_rosati@brown.edu Principal Investigator: John Reagan, MD Less <<
NCT03587662	Kidney Medullary Carcinoma ... More >> Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Less <<	Phase 2	Recruiting	January 6, 2021	United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: M. pmsaouel@mdanderson.org Less <<
NCT03170882	Relapsed and/or Refractory Mul... More >>tiple Myeloma Less <<	Phase 2 Phase 3	Recruiting	March 31, 2023	-
NCT02513498	Chronic Graft Versus Host Dise... More >>ase Less <<	Phase 2	Completed	-	United States, Florida ... More >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Washington Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT02447887	Metastatic Renal Cell Carcinom... More >>a RCC Less <<	Phase 1 Phase 2	Terminated(IRB study closure f... More >>acilitated by Investigator) Less <<	-	United States, Pennsylvania ... More >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT00932698	Relapsed and Refractory Multip... More >>le Myeloma Less <<	PHASE1	COMPLETED	2017-05-23	H. Lee Moffitt Cancer Center, ... More >>Tampa, Florida, 33617, United States\|Emory University, Atlanta, Georgia, 30322, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States\|M.D. Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02168101	Multiple Myeloma	Phase 2	Active, not recruiting	January 2019	United States, Colorado ... More >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Tennessee Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 United States, Texas Texas Transplant Institute San Antonio, Texas, United States, 78229 Less <<
NCT03757221	Multiple Myeloma	Phase 2	Not yet recruiting	December 31, 2025	-
NCT03173092	Multiple Myeloma	Phase 4	Recruiting	November 30, 2023	-
NCT01939899	Follicular Lymphoma	Phase 2	Completed	-	United States, Massachusetts ... More >> Boston, Massachusetts, United States United States, New York New York, New York, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Houston, Texas, United States Belgium Gent, Belgium Leuven, Belgium Wilrijk, Belgium Canada, Quebec Montreal, Quebec, Canada United Kingdom London, United Kingdom Manchester, United Kingdom Newcastle Upon Tyne, United Kingdom Plymouth, United Kingdom Southampton, United Kingdom Sutton, United Kingdom Less <<
NCT02030405	Adult Acute Megakaryoblastic L... More >>eukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia Less <<	PHASE2	TERMINATED	2025-11-15	Stanford University Cancer Ins... More >>titute, Stanford, California, 94305, United States Less <<
NCT02030405	Adult Acute Megakaryoblastic L... More >>eukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia Less <<	PHASE2	TERMINATED	2025-11-15	Stanford University Cancer Ins... More >>titute, Stanford, California, 94305, United States Less <<
NCT02176486	Lupus Nephritis	Phase 1	Terminated(Insufficient enroll... More >>ment, no safety or efficacy concerns) Less <<	-	-
NCT03422874	Neoplasms Lym... More >>phoma Less <<	Phase 1	Withdrawn(Sponsor withdrew sup... More >>port) Less <<	August 4, 2017	United States, New Hampshire ... More >> Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 Less <<
NCT02632396	Mantle Cell Lymphoma	Phase 1 Phase 2	Recruiting	March 2022	United States, Georgia ... More >> Emory University/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Kaylan Dixon 404-778-4449 kaylan.dixon@emory.edu Contact: Vanessa Smith 404-778-2419 vanessa.smith@emory.edu Emory Saint Joseph's Hospital Recruiting Atlanta, Georgia, United States, 30342 Contact: Alicia Escobar 678-843-7029 alicia.m.escobar@emory.edu Less <<
NCT02420847	Bladder Cancer	Phase 1 Phase 2	Active, not recruiting	July 2022	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02302846	Leukemia	PHASE2	TERMINATED	2017-05-30	University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02302846	Leukemia	PHASE2	TERMINATED	2017-05-30	University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT03323151	Mantle-Cell Lymphoma	Phase 1 Phase 2	Recruiting	December 2024	United States, Georgia ... More >> Winship Cancer Institute of Emory University Recruiting Atlanta, Georgia, United States, 30322 Contact: Vanessa Smith 404-778-2214 vanessa.smith@emory.edu Contact: Terra Burney 404-712-0465 terra.l.burney@emory.edu Principal Investigator: Jonathon Cohen, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Oniel Padilla Escalera, MPH 732-235-5972 op100@cinj.rutgers.edu Contact: Dama Bhavsar 732-235-6008 bhavsadm@cinj.rutgers.edu Principal Investigator: Kevin David, MD United States, New York Laura and Isaac Perlmutter Cancer Center at NYU Recruiting New York, New York, United States, 10016 Contact: Angela Tan 646-501-7869 angela.tan@nyumc.org Contact: Nancy Doan 646-501-7921 nancy.doan@nyumc.org Principal Investigator: Catherine Diefenbach, MD United States, Pennsylvania University of Pennsylvania Abramson Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Joseph Vena 215-584-3073 joseph.vena@uphs.upenn.edu Contact: Shannon Cosgrove 215-220-9632 shannon.cosgrove@uphs.upenn.edu Principal Investigator: Daniel Landsburg, MD Reading Hospital/McGlinn Cancer Institute Recruiting West Reading, Pennsylvania, United States, 19611 Contact: Barbara Miller, RN 484-628-8549 barbara.miller@towerhealth.org Contact: Janet Knoblauch, RN 484-628-9376 janet.knoblauch@towerhealth.org Principal Investigator: Terrence Cescon, MD United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Erica Stallard 434-243-2649 Elg9r@hscmail.mcc.vriginia.edu Contact: Kimberly Underwood 434-982-3947 Km3q@hscmail.mcc.virginia.edu Principal Investigator: Craig Portell, MD United States, West Virginia West Virginia University Recruiting Morgantown, West Virginia, United States, 26506 Contact: Sylvia McEwuen 304-293-1683 smcewuen@hsc.wvu.edu Contact: Valerie Phillips 304-581-1880 vphillip@hsc.wvu.edu Principal Investigator: Abraham Kanate, MD United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53792 Contact: Kaitlin Chambers 608-263-5006 kchambers2@wisc.edu Contact: Craig Augustine 608-265-5542 cfaugustine@wisc.edu Principal Investigator: Christopher Fletcher, MD Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Katelyn Gauger 414-805-4587 kgauger@mcw.edu Contact: Kristin Mikulice 414-805-4627 kmikulice@mcw.edu Principal Investigator: Mehdi Hamadani, MD ProHealth Care Recruiting Waukesha, Wisconsin, United States, 53188 Contact: Chanda Miller 262-928-5539 chanda.miller@phci.org Contact: Amelia Crouse 262-928-2143 amelia.crouse@phci.org Principal Investigator: Timothy Wassenaar, MD Less <<
NCT03225417	Hematopoietic Stem Cell Transp... More >>lantation Multiple Myeloma Less <<	Phase 1 Phase 2	Recruiting	May 27, 2023	Spain ... More >> ICO- Hospital Germans Trias i Pujol Not yet recruiting Badalona, Spain Contact: M. Christelle Ferra Coll, MD-PhD Principal Investigator: M. Christelle Ferra Coll, MD-PhD Hospital Clinic de Barcelona Not yet recruiting Barcelona, Spain Contact: Carmen Martínez, MD-Phd CMARTI@clinic.cat Principal Investigator: Carmen Martínez, MD-Phd Hospital de la Santa Creu I Sant Pau Not yet recruiting Barcelona, Spain Contact: Jorge Sierra Gil, MD-Phd jsierra@santpau.cat Principal Investigator: Jorge Sierra Gil, MD-Phd Hospital Universitario Vall D´Hebrón Not yet recruiting Barcelona, Spain Contact: David Valcarcel Ferreira, MD-Phd dvalcarcel.vhebron@me.com Principal Investigator: David Valcarcel Ferreira, MD-Phd Hospital Clinico Universitario Salamanca Not yet recruiting Salamanca, Spain Contact: Lucía Lopez del Corral, MD-PhD lucialopezcorral@usal.es Principal Investigator: Lucía Lopez del Corral, MD-PhD Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain, 41013 Contact: Jose-Antonio Perez-Simon, MD-PhD 0034955013260 ext 0034 josea.perez.simon.sspa@juntadeandalucia.es Contact: Clara M. Rosso, MD 0034955013414 ext 0034 claram.rosso.sspa@juntadeandalucia.es Hospital Clínico Universitario de Valencia Not yet recruiting Valencia, Spain Contact: Carlos Solano Vercet, MD-Phd solano_car@gva.es Principal Investigator: Carlos Solano Vercet, MD-Phd Less <<
NCT03746652	Multiple Myeloma	Phase 2	Not yet recruiting	December 2021	Greece ... More >> General Hospital of Athens "Alexandra" Not yet recruiting Athens, Attica, Greece, 11528 Contact: Evangelos Terpos, Prof. +302103381512 Less <<
NCT02499081	Multiple Myeloma	PHASE2	COMPLETED	2018-05-17	University of Arkansas for Med... More >>ical Science, Little Rock, Arkansas, 72205, United States Less <<
NCT03733691	Newly Diagnosed Multiple Myelo... More >>ma Less <<	Phase 2	Not yet recruiting	February 20, 2024	-
NCT02477215	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	May 1, 2020	United States, Wisconsin ... More >> Froedtert Hospital and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT03748953	Multiple Myeloma	PHASE3	COMPLETED	2023-11-29	Beijing Chaoyang Hospital Capi... More >>tal Medical University, Beijing, Beijing, 100020, China\|Peking University Third Hospital, Beijing, Beijing, 100191, China\|Peking Union Medical College Hospital, Beijing, Beijing, 100730, China\|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China\|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing, Jiangsu, 210029, China\|Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China\|Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, 200001, China\|Shanghai Chang Zheng Hospital, Shanghai, Shanghai, 200003, China\|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, 200025, China\|1st Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China Less <<
NCT02993094	Triple-Negative Breast Cancer	Phase 1 Phase 2	Recruiting	September 2019	Austria ... More >> Klinikum Kreuzschwestern Wels GmbH Recruiting Wels, Oberösterreich, Austria, A-4600 Contact: Renate Pusch, MD Contact: Teresa Bogensperger Principal Investigator: Renate Pusch, MD Universitätsklinik für Innere Medizin Graz Not yet recruiting Graz, Steiermark, Austria, 8036 Contact: Herbert Stöger, MD Principal Investigator: Herbert Stöger, MD Universitätsklinik für Frauenheilkunde Innsbruck Not yet recruiting Innsbruck, Tirol, Austria, 6020 Contact: Daniel Egle, MD Principal Investigator: Daniel Egle, MD Landeskrankenhaus Rankweil Recruiting Rankweil, Vorarlberg, Austria, 6830 Contact: Holger Rumpold, MD Principal Investigator: Holger Rumpold, MD BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie Recruiting Linz, Austria, A-4020 Contact: Andreas Petzer, MD Contact: Martina Lang Principal Investigator: Andreas Petzer, MD KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie Recruiting Linz, Austria, A-4020 Contact: Michael Fridrik, MD Contact: Bettina Pfleger Principal Investigator: Michael Fridrik, MD PMU Salzburg: Universitätsklinik für Innere Medizin III Recruiting Salzburg, Austria, A-5020 Contact: Richard Greil, MD Contact: Michaela Schachner Principal Investigator: Richard Greil, MD Landeskrankenhaus Steyr, Innere Medizin II Onkologie Recruiting Steyr, Austria, A-4400 Contact: Dieter Rossmann, MD Contact: Regina Neuhauser Principal Investigator: Dieter Rossmann, MD AKH Wien Universitätsklinik für Frauenheilkunde: Klin. Abt. f. Allg. Gynäkologie und gynäkologische Onkologie Recruiting Vienna, Austria, A-1090 Contact: Christian Singer, MD Contact: Philipp Pappenscheller Principal Investigator: Christian Singer, MD Less <<
NCT03169361	Relapsed/Refractory Multiple M... More >>yeloma Less <<		COMPLETED	2022-03-08	Takeda Selected Site, Tokyo, J... More >>apan Less <<
NCT02312258	Multiple Myeloma	Phase 3	Recruiting	July 31, 2019	-
NCT03439293	Multiple Myeloma	Phase 2	Recruiting	December 31, 2023	United States, California ... More >> Pacific Cancer Medical Center Recruiting Anaheim, California, United States, 92801 United States, Colorado Colorado Blood Cancer Institute Not yet recruiting Denver, Colorado, United States, 80218-1230 United States, Florida SCRI - Florida Cancer Specialists - Panhandle Not yet recruiting Tallahassee, Florida, United States, 32308 United States, Missouri Research Medical Center - Kansas City Not yet recruiting Kansas City, Missouri, United States, 64132 United States, Tennessee SCRI - Tennessee Oncology - Nashville - Centennial Not yet recruiting Nashville, Tennessee, United States, 58014 United States, Texas The University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030-4017 Czechia Fakultni Nemocnice Olomouc Not yet recruiting Olomouc, Olomoucky, Czechia, 77900 Fakultni Nemocnice Kralovske Vinohrady Not yet recruiting Praha 10, Praha, Czechia, 100 34 Fakultni Nemocnice Ostrava Not yet recruiting Ostrava - Poruba, Severomoravsky KRAJ, Czechia, 708 52 Fakultni Nemocnice Brno Not yet recruiting Brno, Czechia, 625 00 Onkologicka klinika Vseobecna fakultni nemocnice v Praze a 1 Not yet recruiting Praha, Czechia, 128 08 France Hopital Saint-Antoine Not yet recruiting Paris, Ile-de-france, France, 75012 Hopital Claude Huriez Not yet recruiting Lille Cedex, NORD Pas-de-calais, France, 59037 Hopital Hotel Dieu Not yet recruiting Nantes Cedex 1, PAYS DE LA Loire, France, 44093 Centre Hospitalier Lyon Sud Not yet recruiting Pierre Benite Cedex, Rhone-alpes, France, 69495 Greece Evaggelismos General Hospital Not yet recruiting Athens, Attica, Greece, 10676 Alexandra General Hospital of Athens Not yet recruiting Athens, Attica, Greece, 11528 University General Hospital of Patras Panagia I Voithia Not yet recruiting Patras, Peloponnese, Greece, 26504 Netherlands Medisch Centrum Leeuwarden Not yet recruiting Leeuwarden, Friesland, Netherlands, 8934 AD Vrije Universiteit Medisch Centrum Not yet recruiting Amsterdam, Noord-holland, Netherlands, 1081 HV Albert Schweitzer Ziekenhuis Dordwijk Not yet recruiting Dordrecht, South Holland, Netherlands, 3300 AK Erasmus Medisch Centrum Not yet recruiting Rotterdam, Zuid-holland, Netherlands, 3015 CE Universitair Medisch Centrum Utrecht Not yet recruiting Utrecht, Netherlands, 3584 CX Poland Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi Not yet recruiting Lodz, Lodzkie, Poland, 93-510 Szpital Uniwersytecki w Krakowie Not yet recruiting Krakow, Malopolskie, Poland, 31-501 Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza Not yet recruiting Brzozow, Podkarpackie, Poland, 36-200 Szpitale Pomorskie Spolka z ograniczona odpowiedzialnoscia Not yet recruiting Gdynia, Pomorskie, Poland, 81-519 Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich Not yet recruiting Chorzow, Slaskie, Poland, 41-500 Less <<
NCT02181413	Multiple Myeloma ... More >> Autologous Stem Cell Transplant Less <<	Phase 3	Active, not recruiting	June 25, 2025	-
NCT03608501	Multiple Myeloma	Phase 2	Not yet recruiting	May 31, 2023	-
NCT03618537	AL Amyloidosis	Phase 2	Recruiting	August 2021	United States, New Jersey ... More >> Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Heather Landau, MD 212-639-8808 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Heather Landau, MD 212-639-8808 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Heather Landau, MD 212-639-8808 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Heather Landau, MD 212-639-8808 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Heather Landau, MD 212-639-8808 Contact: Hani Hassoun, MD 212-639-3228 Principal Investigator: Heather Landau, MD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Heather Landau, MD 212-639-8808 Less <<
NCT03616782	Mantle Cell Lymphoma	PHASE2	RECRUITING	2026-05-31	Kosin University Gospel Hospit... More >>al, Busan, Western, 49267, Korea, Republic of Less <<
NCT02898259	B Cell Lymphoma ... More >> Lymphoma Less <<	Phase 1 Phase 2	Recruiting	June 2024	United States, Ohio ... More >> University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44106 Contact: Paolo Caimi, MD 800-641-2422 Paolo.Caimi@uhhospitals.org Principal Investigator: Paolo Caimi, MD Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Brian Hill, MD, PhD 216-444-9451 Hillb2@ccf.org Principal Investigator: Brian Hill, MD, PhD Less <<
NCT02946047	HIV	Phase 1 Phase 2	Recruiting	September 2020	United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: James Allen 507-255-9899 allen.james1@mayo.edu Less <<
NCT03547700	Lymphoma, T-Cell, Peripheral	Phase 1 Phase 2	Recruiting	July 2021	United States, Michigan ... More >> University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Ryan Wilcox, M.D. 734-615-1482 rwilcox@med.umich.edu Contact: Sumana Devata 734-615-7813 sdevata@med.umich.edu Less <<
NCT03283917	Hematopoietic/Lymphoid Cancer ... More >> Amyloid Light Chain (AL) Amyloidosis Less <<	Phase 1	Recruiting	April 2020	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact hclee@mdanderson.org Less <<
NCT02578511	Acute Lymphoblastic Leukemia i... More >>n Complete Remission\|Lymphoblastic Lymphoma in Complete Remission\|Mixed Phenotype Acute Leukemia in Complete Remission Less <<	PHASE1	WITHDRAWN	2018-02-13	Froedtert & the Medical Colleg... More >>e of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT02942095	Solid Tumors	Phase 1	Recruiting	March 2020	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact dshong@mdanderson.org Less <<
NCT03082677	Myeloid Hematologic Malignancy... More >>\|Lymphoid Hematologic Malignancy Less <<	PHASE2	COMPLETED	2021-09-02	Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less <<
NCT02924272	Multiple Myeloma\|Lymphoma\|Amyl... More >>oidosis Less <<	PHASE2	COMPLETED	2024-07-03	Emory University, Atlanta, Geo... More >>rgia, 30322, United States\|Appalachian Regional Healthcare, Hazard, Kentucky, 41701, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States\|UZ Leuven, Leuven, 3000, Belgium\|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 1X5, Canada\|University Health Network, Toronto, Ontario, M5G 2M9, Canada\|Peking University Third Hospital, Beijing, Beijing, 100191, China\|Peking Union Medical College Hospital, Beijing, Beijing, 100730, China\|1st Affiliated Hospital of Zhejiang University, Hangzhou, 310003, China\|Shanghai Chang Zheng Hospital, Shanghai, 200003, China\|Laiko General Hospital of Athens, Athens, Attiki, 115 27, Greece\|University of Athens Medical School - Regional General Hospital Alexandra, Athens, 11528, Greece\|Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku, Tokyo, 113-8677, Japan\|Japanese Red Cross Medical Center, Shibuya-Ku, Tokyo, 150-8935, Japan\|Asan Medical Center - PPDS, Seoul, 5505, Korea, Republic of\|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Slaskie, 41-500, Poland\|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, 93-510, Poland\|Centrum Onkologii Ziemi Lubelskiej, Lublin, 20-090, Poland\|MTZ Clinical Research Sp z o o, Warszawa, 02-106, Poland\|National University Hospital, Singapore, 119082, Singapore\|Complejo Asistencial Universitario de Salamanca H. Clinico, Salamanca, 37007, Spain\|Hospital Universitario de Donostia, San Sebastian, 20014, Spain\|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sodermanlands Lan, Sweden\|Skanes Universitetssjukhus Lund, Lund, 22185, Sweden\|Karolinska Universitetssjukhuset Solna, Stockholm, SE-17176, Sweden Less <<
NCT02630030	Glioblastoma	EARLY_PHASE1	COMPLETED	2020-09-03	Emory University/Winship Cance... More >>r Institute, Atlanta, Georgia, 30322, United States Less <<
NCT03770260	Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less <<	Phase 1	Not yet recruiting	September 30, 2021	-
NCT04028115	Multiple Myeloma	PHASE2	COMPLETED	2024-04-01	Odense University Hospital, Od... More >>ense, 5000, Denmark Less <<
NCT03888534	Precursor Cell Lymphoblastic L... More >>eukemia-lymphoma Less <<	PHASE1	WITHDRAWN	2022-08-30	University of Mississippi Medi... More >>cal Center, Jackson, Mississippi, 39216, United States\|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States\|St Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States\|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, 8035, Spain\|C.H. Regional Reina Sofia, Cordoba, 14004, Spain\|Hospital Universitario La Paz, Madrid, 28046, Spain Less <<
NCT04837131	Systemic Sclerosis\|Scleroderma... More >>\|Diffuse Systemic Sclerosis\|Diffuse Scleroderma\|Diffuse Cutaneous Systemic Sclerosis\|Diffuse Cutaneous Scleroderma\|Progressive Systemic Sclerosis\|Progressive Scleroderma\|Scleroderma, Systemic\|Scleroderma, Diffuse\|Scleroderma;Progressive\|Systemic Sclerosis, Diffuse\|Systemic; Sclerosis, Progressive\|Scleroderma of Lung\|Scleroderma With Pulmonary Involvement\|Systemic Sclerosis Pulmonary\|Systemic Sclerosis With Lung Involvement\|Interstitial Lung Disease\|Pulmonary Fibrosis Interstitial Less <<	PHASE2	TERMINATED	2024-02-23	Mayo Clinic in Arizona, Scotts... More >>dale, Arizona, 85259, United States Less <<

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1072833-77-2
Formula :	C₁₄H₁₉BCl₂N₂O₄
M.W :	361.03
SMILES Code :	CC(C)C[C@@H](B(O)O)NC(CNC(C1=CC(Cl)=CC=C1Cl)=O)=O
Synonyms :	MLN2238
MDL No. :	MFCD18251438
InChI Key :	MXAYKZJJDUDWDS-LBPRGKRZSA-N
Pubchem ID :	25183872

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Jurkat	25nM	24 hours	To investigate the effect of ixazomib on cell cycle, chromatin modification, and DNA repair processes, results showed down-regulation of these processes in ixazomib sensitive lymphoma cells.	PMC5315412
L540	25nM	24 hours	To investigate the effect of ixazomib on cell cycle, chromatin modification, and DNA repair processes, results showed down-regulation of these processes in ixazomib sensitive lymphoma cells.	PMC5315412
L428	25nM	24 hours	To investigate the effect of ixazomib on cell cycle, chromatin modification, and DNA repair processes, results showed down-regulation of these processes in ixazomib sensitive lymphoma cells.	PMC5315412
COS-7 cells	30 nM	6 hours	Investigated the effect of Ixazomib on the ubiquitination of OAT3, showing that Ixazomib significantly increased the accumulation of ubiquitinated OAT3.	PMC7997269
HCT116	5-10 µM	24 hours	Ixazomib induced apoptosis, detected by Annexin V/PI staining.	PMC6370389
HCT116	10 µM	24 hours	Ixazomib significantly increased DR5 mRNA and protein expression.	PMC6370389
J-Lat 10.6 cells	100 nM	48 hours	Ixazomib significantly increased the proportion of GFP+ cells, indicating its induction of HIV production. Compared to ixazomib alone, the combination of venetoclax and ixazomib significantly reduced GFP expression, suggesting enhanced death of HIV-infected cells with the combination treatment.	PMC8315902

SCID mice	Human lymphoma xenograft models	Intraperitoneal injection	25 mg/kg	daily for 14 days	To evaluate the anti-tumor activity of ixazomib in human lymphoma xenograft models, results showed significant inhibition of tumor growth and improved survival.	PMC5315412
Nude mice	HCT116 xenograft model	Oral	20 mg/kg enzalutamide + 5 mg/kg MK-8776	Every other day for two weeks	Ixazomib significantly inhibited tumor growth, and the loss of DR5 attenuated its antitumor activity.	PMC6370389
Mice	Chronic graft-versus-host disease model	Subcutaneous injection	0.36 or 0.72mg/kg	Daily for three weeks	Delayed administration of Ixazomib significantly prolonged survival, decreased the risk of chronic graft-versus-host disease, and preserved the graft-versus-leukemia effect.	PMC8636253

{[proInfo.proName]}

CAS No.: 1072833-77-2

{[proInfo.proName]}

CAS No.: 1072833-77-2

Product Citations

Alternative Products

Product Details of Ixazomib

Safety of Ixazomib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.77mL 0.55mL 0.28mL	13.85mL 2.77mL 1.38mL	27.70mL 5.54mL 2.77mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed